Joint with: Immune Cell Therapies: Advances in Cancer and Autoimmune Disease
Cancer Immunotherapy: Clinical Lessons to New Modalities
Mar 16–19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Christian U Blank, Stefani Spranger and Anna Christina Obenauf
In Person
On Demand
Mar 16–19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Christian U Blank, Stefani Spranger and Anna Christina Obenauf
Available Formats:
Supported by:
In Person
On Demand
Available Formats: = In Person = On Demand
Merchandise Options
Registration Options
Sunday, March 16, 2025
Fundraising
Booking Function
Registration
4:00–8:00 PM
Van Horne Foyer
Welcome Mixer
6:00–8:00 PM
Van Horne Foyer
Monday, March 17, 2025
Breakfast
7:00–8:00 AM
President's Hall
Welcome and Keynote Session (Joint)
8:00–9:30 AM
Van Horne A
* Anna Christina Obenauf, Research Institute of Molecular Pathology
Session Chair
Session Chair
* Katy Rezvani, University of Texas MD Anderson Cancer Center
Session Chair
Session Chair
Carl H. June, University of Pennsylvania
Cell Therapies: Current State of the Art
Cell Therapies: Current State of the Art
Ton N. Schumacher, Netherlands Cancer Institute
Dissecting T Cell Recognition of Cancer
Dissecting T Cell Recognition of Cancer
Coffee Break
9:30–9:50 AM
Van Horne Foyer
Award Recipient Acknowledgement
9:50–9:55 AM
Van Horne A
Overcoming Challenges in Immune and Cell Therapy: Insights into Mechanisms of Failure and Solutions (Joint)
9:55–12:00 PM
Van Horne A
* Nathan Singh, Washington University School of Medicine
Genomic Regulation of CAR T Cell Driven Dysfunction
Genomic Regulation of CAR T Cell Driven Dysfunction
* Anna Christina Obenauf, Research Institute of Molecular Pathology
Rational Combination Therapies to Stimulate the APC Compartment
Rational Combination Therapies to Stimulate the APC Compartment
May Daher, MD Anderson Cancer Center
Metabolic Interventions to Enhance Adoptive Cellular Therapies
Metabolic Interventions to Enhance Adoptive Cellular Therapies
Christopher Harvey, Phenomic
AI/ML-Driven Discovery of a Novel Proteoglycan for Precision Targeting of Solid Tumors by T Cell Engagers
AI/ML-Driven Discovery of a Novel Proteoglycan for Precision Targeting of Solid Tumors by T Cell Engagers
Poster Setup
12:00–1:00 PM
Van Horne C
On Own for Lunch
12:00–3:30 PM
Poster Viewing
1:00–10:00 PM
Van Horne C
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
3:30–4:30 PM
Van Horne B
Lauren E Milling, Harvard Medical School
A STUB1-CHIC2 Complex Decreases IL-27Rα Expression on CD8+ T Cells To Restrain Tumor Immunity
A STUB1-CHIC2 Complex Decreases IL-27Rα Expression on CD8+ T Cells To Restrain Tumor Immunity
Alice O Kamphorst, Icahn School of Medicine at Mount Sinai
ICOS Limits Memory-like Properties and Function of Exhausted PD-1+ CD8 T Cells
ICOS Limits Memory-like Properties and Function of Exhausted PD-1+ CD8 T Cells
* Derek A Wainwright, Loyola University Chicago Stritch School of Medicine
IDO1 - Revising Dogma to Improve Control
IDO1 - Revising Dogma to Improve Control
Henrique Borges da Silva, Mayo Clinic Arizona
The eATP Receptor P2RX7 Promotes Optimal Progenitor Exhausted CD8+ T Cell Responses To Anti-PD1 Blockade
The eATP Receptor P2RX7 Promotes Optimal Progenitor Exhausted CD8+ T Cell Responses To Anti-PD1 Blockade
Coffee Available
4:30–5:00 PM
Van Horne Foyer
DC and Alternative Immune Cell Activation
5:00–7:00 PM
Van Horne B
* Amy C. Fan, UCSF
Interrogating Immune Archetypes & Tumor Sampling to Inform Therapy
Interrogating Immune Archetypes & Tumor Sampling to Inform Therapy
Susan M Kaech, The Salk Institute
Metabolic Control of Anti-Tumor Immunity
Metabolic Control of Anti-Tumor Immunity
Cansu Cimen Bozkus, Icahn School of Medicine at Mount Sinai
Personalized Neoantigen Vaccines in Cancer Immunotherapy
Personalized Neoantigen Vaccines in Cancer Immunotherapy
Joanna Pozniak, VIB
Short Talk: Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma With an Immune-Excluded Phenotype
Short Talk: Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma With an Immune-Excluded Phenotype
Fiona Chatterjee, Massachusetts Institute of Technology
Short Talk: Tumor-resident CD103+ CD11b+ Dendritic Cells are Associated with Poor Anti-Tumor Immunity in Ovarian Cancer
Short Talk: Tumor-resident CD103+ CD11b+ Dendritic Cells are Associated with Poor Anti-Tumor Immunity in Ovarian Cancer
Social Hour with Lite Bites
7:00–8:00 PM
President's Hall
Poster Session 1
7:30–10:00 PM
Van Horne C
Tuesday, March 18, 2025
Breakfast
7:00–8:00 AM
President's Hall
Neoadjuvant Cancer Immunotherapy, Where are We Standing
8:00–10:15 AM
Van Horne B
* Tina Cascone, University of Texas MD Anderson Cancer Center
Neoadjvant Cancer Immunotherapy in NSCLC
Neoadjvant Cancer Immunotherapy in NSCLC
Christian U Blank, Netherlands Cancer Institute - NKI-AVL
Personalized Neoadjuvant Cancer Immunotherapy in Melanoma
Personalized Neoadjuvant Cancer Immunotherapy in Melanoma
Philip Georg Demaerel, UZLeuven
Short Talk: Insights from Single-Cell Resolution Spatial Transcriptomic Analysis Before and During Neoadjuvant Immunotherapy in Advanced Melanoma
Short Talk: Insights from Single-Cell Resolution Spatial Transcriptomic Analysis Before and During Neoadjuvant Immunotherapy in Advanced Melanoma
Nicholas J Salgia, Roswell Park Comprehensive Cancer Center
Short Talk: Untangling and Applying the Paradoxical Immune Sensitivity of Sarcomatoid Renal Cell Carcinoma
Short Talk: Untangling and Applying the Paradoxical Immune Sensitivity of Sarcomatoid Renal Cell Carcinoma
Jaroslav Zak, University of Utah
Short Talk: Mechanistic Insights into the Paradoxical Efficacy of JAK and PD1 Inhibition in Cancer Immunotherapy
Short Talk: Mechanistic Insights into the Paradoxical Efficacy of JAK and PD1 Inhibition in Cancer Immunotherapy
Coffee Break
9:00–9:20 AM
Van Horne Foyer
On Own for Lunch
10:15–5:00 PM
Poster Setup
11:00–1:00 PM
Van Horne C
Poster Viewing
1:00–10:00 PM
Van Horne C
Career Roundtable (Joint)
3:00–4:30 PM
Van Horne B
Wolfgang Karl Kastenmueller, Institute of Systems Immunology, Max-Planck Research Group
Professor and Director
Professor and Director
Rayne H. Rouce, Baylor College of Medicine
Associate Professor
Associate Professor
Kristian Hedstrom, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Chief Scientific Officer
Chief Scientific Officer
Frank P Stegmeier, Curie.Bio
CSO Partner
CSO Partner
Fabiola V Rivas, Immunity
Deputy Editor
Deputy Editor
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Integrative Strategies in Cancer Immunotherapy: Harnessing Myeloid Cells, NK Cells, Unconventional T Cells and More
5:00–7:00 PM
Van Horne B
* Stefani Spranger, Massachusetts Institute of Technology
DC Determine Quality of T Cell Responses
DC Determine Quality of T Cell Responses
Wolfgang Karl Kastenmueller, Institute of Systems Immunology, Max-Planck Research Group
Affinity Selection Phase during CD8 T Cell Priming
Affinity Selection Phase during CD8 T Cell Priming
Ann F. Cheung, Dragonfly Therapeutics
NK Cell Therapeutics
NK Cell Therapeutics
Chenyu Zhang, University of California, Berkeley
Short Talk: Intra-tumoral Treg Ablation Activates a CD4-NK Cell Axis to Control MHC Class I-deficient Tumors
Short Talk: Intra-tumoral Treg Ablation Activates a CD4-NK Cell Axis to Control MHC Class I-deficient Tumors
Richard P. Tobin, University of Colorado Anschutz Medical Campus
Short Talk: Alterations in MAIT Cells Frequency and Function During Melanoma Development and Treatment
Short Talk: Alterations in MAIT Cells Frequency and Function During Melanoma Development and Treatment
Social Hour with Lite Bites
7:00–8:00 PM
President's Hall
Poster Session 2
7:30–10:00 PM
Van Horne C
Wednesday, March 19, 2025
Breakfast
7:00–8:00 AM
President's Hall
Cytokine/Chemokine Biology and Engineering
8:00–11:00 AM
Van Horne B
Howard L. Kaufman, Massachusetts General Hospital and Ankyra Therapeutics
Remote Presentation: Anchored Cytokines for the Treatment of Cancer
Remote Presentation: Anchored Cytokines for the Treatment of Cancer
Joanna R Groom, Walter and Eliza Hall Institute of Medical Research
Chemokine Signaling and Positioning in the LN
Chemokine Signaling and Positioning in the LN
* Jamie Spangler, Johns Hopkins University
Cytokine Engineering
Cytokine Engineering
Sameer Chopra, Werewolf Therapeutics Inc.
Short Talk: Unmasking the Potential of Cytokines for Cancer Immunotherapy: Lessons Learned from the Early Clinical Development of Tumor-activated IL-2 and IL-12 INDUKINE Molecules
Short Talk: Unmasking the Potential of Cytokines for Cancer Immunotherapy: Lessons Learned from the Early Clinical Development of Tumor-activated IL-2 and IL-12 INDUKINE Molecules
Xinyi Tu, Mayo Clinic
Short Talk: A New PD-L1 Antibody Degrades PD-L1 and Sensitizes Cancer Cells to Cytotoxic Therapy
Short Talk: A New PD-L1 Antibody Degrades PD-L1 and Sensitizes Cancer Cells to Cytotoxic Therapy
Michelle Nathalie von Locquenghien, Weizmann Institute of Science
Short Talk: Development of Novel “Myeloid-Targeted Immunocytokine and (NK)T cell Enhancer” (MiTE) with Tumor-Conditioned Cytokine Activity for Cancer Treatment Using Single Cell Genomics and AI
Short Talk: Development of Novel “Myeloid-Targeted Immunocytokine and (NK)T cell Enhancer” (MiTE) with Tumor-Conditioned Cytokine Activity for Cancer Treatment Using Single Cell Genomics and AI
Coffee Break
9:00–9:20 AM
Van Horne Foyer
On Own for Lunch
11:00–3:15 PM
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
3:15–4:30 PM
Van Horne B
* Ana Marcu, Genentech
Developing Discovery Proteomics Technologies to Elucidate HLA Neoantigen Presentation
Developing Discovery Proteomics Technologies to Elucidate HLA Neoantigen Presentation
Feng Han, DKFZ (German Cancer Research Center)
CMTM4/6 as Novel Therapeutic Targets to Sensitize Hepatocellular Carcinoma to Immunotherapy
CMTM4/6 as Novel Therapeutic Targets to Sensitize Hepatocellular Carcinoma to Immunotherapy
Caitlin O'Brien-Ball, University of Oxford
Characterising Novel Protein Tools for Potentiating T Cell Activation by Inhibiting PD-1
Characterising Novel Protein Tools for Potentiating T Cell Activation by Inhibiting PD-1
Amanda G Heard, University of Kansas Medical Center
Progesterone Promotes Immunosuppression in Murine Mammary Tumors by Modulating T Cell Infiltration and Function
Progesterone Promotes Immunosuppression in Murine Mammary Tumors by Modulating T Cell Infiltration and Function
Trevor E Frederick, Rutgers University
Novel Type I-Type III IFN Fusion Proteins For Cancer Therapy
Novel Type I-Type III IFN Fusion Proteins For Cancer Therapy
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Engineering in Cancer Immunotherapy to Enhance Efficacy (Joint)
5:00–6:30 PM
Van Horne A
Rosandra Natasha Kaplan, NCI, National Institutes of Health
Remote Presentation: Engineering of Myeloid Cells
Remote Presentation: Engineering of Myeloid Cells
Jaehyuk Choi, Northwestern University
Nature Inspired Design
Nature Inspired Design
* Julia Carnevale, University of California, San Francisco
CRISPR-Based T Cell Editing to Enhance Cell Therapy
CRISPR-Based T Cell Editing to Enhance Cell Therapy
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Joint)
6:30–7:00 PM
Van Horne A
Social Hour with Lite Bites
7:00–8:00 PM
President's Hall
Entertainment
8:00–9:00 PM
Van Horne B
Thursday, March 20, 2025
Departure
12:00–11:59 PM
Subscribe for Updates